• Lakefront Biotherapeutics appointed Mehdi Shahidi as an independent non-executive director, effective November 2, 2026.
• He replaces Paulo Fontoura, who resigned in July 2026 following his appointment as Sanofi's global head of R&D.
• Shahidi previously served as Boehringer Ingelheim's global head of medicine and chief medical officer, with over 20 years of biopharma experience.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakefront Biotherapeutics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611021601OMX_____CNEWS_EN_GNW1001301362_en) on November 02, 2026, and is solely responsible for the information contained therein.